Acorn Capital Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Acorn Capital Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$967K	Sell	234,039 -39,310	-14%	-$147K	0.27%	20
2025 Q4	$1.09M	Hold	273,349	–	–	0.37%	19
2025 Q3	$935K	Buy	273,349 +119,619	+78%	+$308K	0.47%	18
2025 Q2	$292K	Sell	153,730 -89,958	-37%	-$368K	0.19%	21
2025 Q1	$1.75M	Hold	243,688	–	–	1.17%	16
2024 Q4	$5.36M	Buy	+243,688	New	+$3.88M	2.89%	13

Other funds holding XFOR

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Acorn Capital Advisors's XFOR Position: Q1 2026 in Review

Acorn Capital Advisors reduced its X4 Pharmaceuticals (XFOR) stake by 14% in Q1 2026, selling an estimated $147K and leaving 234,039 shares worth $967K. The position accounts for 0.27% of the portfolio, ranked #20.

Acorn Capital Advisors first reported a position in XFOR in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.36M in Q4 2024. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

Acorn Capital Advisors held 234,039 shares of X4 Pharmaceuticals worth $967K as of Q1 2026.
Acorn Capital Advisors sold 39,310 X4 Pharmaceuticals shares in Q1 2026, an estimated $147K.
X4 Pharmaceuticals made up 0.27% of Acorn Capital Advisors's portfolio in Q1 2026, its #20 holding.
Acorn Capital Advisors first reported a position in X4 Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Acorn Capital Advisors's X4 Pharmaceuticals position peaked at $5.36M in Q4 2024.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.